JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 24, 2004; DOI: 10.1124/jpet.103.060293


0022-3565/04/3093-959-969$20.00
JPET 309:959-969, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.060293v1
309/3/959    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lindsey, K. P.
Right arrow Articles by Howell, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindsey, K. P.
Right arrow Articles by Howell, L. L.

NEUROPHARMACOLOGY

Effects of Dopamine Transporter Inhibitors on Cocaine Self-Administration in Rhesus Monkeys: Relationship to Transporter Occupancy Determined by Positron Emission Tomography Neuroimaging

Kimberly P. Lindsey, Kristin M. Wilcox, John R. Votaw, Mark M. Goodman, Christophe Plisson, F. Ivy Carroll, Kenner C. Rice, and Leonard L. Howell

Yerkes National Primate Research Center (K.P.L., K.M.W., L.L.H.), Departments of Radiology (J.R.V., M.M.G., C.P.) and Psychiatry and Behavioral Sciences (L.L.H.), Emory University, Atlanta, Georgia; Research Triangle Institute (F.I.C.), Research Triangle Park, North Carolina; and Laboratory of Medicinal Chemistry (K.C.R.), National Institute of Diabetes and Digestive and Kidney Diseases, Department of Health and Human Services, National Institutes of Health, Bethesda, Maryland

The dopamine transporter (DAT) is a critical recognition site for cocaine and contributes to its significant abuse liability. Accordingly, the development of compounds that target the DAT represents a logical approach in the pharmacological treatment of cocaine abuse. The present study characterized the effects of DAT inhibitors as pretreatments in rhesus monkeys trained to self-administer cocaine under a second-order schedule of i.v. drug delivery. The drugs also were substituted for cocaine to characterize their effectiveness in maintaining drug self-administration. Positron emission tomography neuroimaging with [18F]8-(2-[18F]fluoroethyl)-2{beta}-carbomethoxy-3{beta}-(4-chlorophenyl) nortropane established the DAT occupancy associated with behaviorally relevant doses of each drug. The drugs studied included a selective DAT inhibitor, [1-(2[bis(4-fluorophenyl-) methoxy]ethyl)-4-(3-phenylpropyl)piperazine] bimesylate hydrate (GBR 12909); an inhibitor with equal potency at dopamine and norepinephrine transporters, [3{beta}-(4-chlorophenyl)tropane-2{beta}-(3-phenylisoxazol-5-yl)] HCl (RTI-177); and a nonselective inhibitor of dopamine, norepinephrinem and serotonin transporters, [(-)-3{beta}-(3'-methyl-4-chlorophenyl)tropane-2{beta}-carboxylic acid methyl ester] tartrate (RTI-112). All drugs produced dose-related reductions in cocaine self-administration. Doses of GBR 12909 and RTI-177 that reduced responding by 50% (ED50) resulted in DAT occupancies of 67 ± 5 and 73 ± 5%, respectively. In contrast, DAT occupancy was below the limit of detection for the ED50 dose of RTI-112. Both GBR 12909 and RTI-177 reliably maintained drug self-administration, and DAT occupancies at doses that maintained peak rates of responding were 57 ± 1 and 92 ± 7%, respectively. In contrast, RTI-112 failed to maintain robust drug self-administration in any subject. The results indicate that selective DAT inhibitors may require high DAT occupancy to reduce cocaine self-administration and maintain drug self-administration. Moreover, the behavioral profile of DAT inhibitors may be influenced by actions at other monoamine transporters.


Received September 18, 2003; accepted February 19, 2004.

Address correspondence to: Dr. Leonard L. Howell, Yerkes National Primate Research Center, Emory University, 954 Gatewood Rd. NE, Atlanta, GA 30329. E-mail: leonard{at}rmy.emory.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
L. L. Howell, F. I. Carroll, J. R. Votaw, M. M. Goodman, and H. L. Kimmel
Effects of Combined Dopamine and Serotonin Transporter Inhibitors on Cocaine Self-Administration in Rhesus Monkeys
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 757 - 765.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
F. J. Vocci, J. Acri, and A. Elkashef
Medication Development for Addictive Disorders: The State of the Science
Am J Psychiatry, August 1, 2005; 162(8): 1432 - 1440.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
M. A. Nader and P. W. Czoty
PET Imaging of Dopamine D2 Receptors in Monkey Models of Cocaine Abuse: Genetic Predisposition Versus Environmental Modulation
Am J Psychiatry, August 1, 2005; 162(8): 1473 - 1482.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.